LeFrock J L, Ristuccia A M, Ristuccia P A, Quenzer R W, Haggerty P G, Allen J E, Lettau L A, Schwartz R, Appleby D
Therapeutic Research Institute, Sarasota, Florida 34239.
Eur J Surg Suppl. 1992(567):9-13.
Teicoplanin is a new glycopeptide antibiotic with activity against Gram-positive bacteria, including methicillin-resistant organisms. Teicoplanin is administered once daily, either intravenously or intramuscularly. Teicoplanin was given once daily, intravenously or intramuscularly, in the treatment of hospitalized or ambulatory patients with Gram-positive bone or joint infections. A total of 90/98 patients were evaluated for efficacy; 41 had acute osteomyelitis, 41 had chronic osteomyelitis, and 8 had septic arthritis. At the end of therapy, 37 acute osteomyelitis patients were cured/improved with a 90% cure rate at 6-month follow-up; 2 relapsed and 1 failed. At the end of therapy 30 chronic osteomyelitis patients were cured/improved with an 88% cure rate at 6-month follow-up; 2 relapsed and 1 failed. 100% of the septic arthritis patients were cured at the end of therapy and at 1-month follow-up. The most common bacterial isolates cultured from bone were S. aureus (39 isolates), S. epidermidis (11 isolates), other coagulase-negative staphylococci (20 isolates), enterococci (6 isolates), and other streptococcal species (20 isolates). The most common bacterial isolates cultured from joint fluid were S. aureus (6 isolates) and S. epidermidis (2 isolates). All patients tolerated the intramuscular or intravenous routes of administration well. Adverse reactions were mild and most cases did not require discontinuation of therapy. The majority of therapy was administered on an outpatient basis. Teicoplanin was safe, effective, convenient and relatively well tolerated in patients with acute or chronic osteomyelitis or septic arthritis.
替考拉宁是一种新型糖肽类抗生素，对革兰氏阳性菌具有活性，包括耐甲氧西林的微生物。替考拉宁每日给药一次，可静脉注射或肌肉注射。在治疗住院或门诊的革兰氏阳性骨或关节感染患者时，替考拉宁通过静脉注射或肌肉注射每日给药一次。总共对90/98例患者进行了疗效评估；41例患有急性骨髓炎，41例患有慢性骨髓炎，8例患有化脓性关节炎。治疗结束时，37例急性骨髓炎患者治愈/好转，6个月随访时治愈率为90%；2例复发，1例治疗失败。治疗结束时，30例慢性骨髓炎患者治愈/好转，6个月随访时治愈率为88%；2例复发，1例治疗失败。100%的化脓性关节炎患者在治疗结束时和1个月随访时治愈。从骨中培养出的最常见细菌分离株为金黄色葡萄球菌（39株）、表皮葡萄球菌（11株）、其他凝固酶阴性葡萄球菌（20株）、肠球菌（6株）和其他链球菌属（20株）。从关节液中培养出的最常见细菌分离株为金黄色葡萄球菌（6株）和表皮葡萄球菌（2株）。所有患者对肌肉注射或静脉注射给药途径耐受性良好。不良反应轻微，大多数病例无需停药。大多数治疗在门诊进行。替考拉宁对于急性或慢性骨髓炎或化脓性关节炎患者是安全、有效、方便且耐受性相对良好的。
